Loading stock data…
RVTY
$104.13+3.83 (+3.82%)
After Hours$102.25-1.88 (-1.81%)· Last close Jun 9
Revvity, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revvity, Inc. in the Healthcare sector is trading at $104.13. Wall Street consensus targets $113.64 (14 analysts), implying a +9.1% move over the next 12 months. The stock is currently 12% below its 52-week high of $118.30, remaining 9.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +9.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$104.13
Potential Downside
0%
Whystock Fair Value$104.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$113.64+9.1%
Range$90.00 – $145.00
Fundamentals
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.27%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.34%
Volume
Today's trading volume
997,245
Recent News
Revvity (RVTY) Valuation Check After China Immunodiagnostics Exit Plan And Solid First Quarter Results
Revvity (RVTY) is back in focus after announcing plans to divest its China immunodiagnostics business, a unit facing policy and cash flow headwinds, alongside reporting solid first quarter revenue and margin figures. See our latest analysis for Revvity. The stock has given up some ground in the past week, with a 1-day share price decline of 3.94% and a 7-day share price return of 2.14% lower. However, the 90-day share price return is up 8.94% and the 1-year total shareholder return is 6.21%,...
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Research Tools & Consumables Stocks Q1 In Review: Revvity (NYSE:RVTY) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at research tools & consumables stocks, starting with Revvity (NYSE:RVTY).
Is Danaher Stock Underperforming the S&P 500?
Danaher has underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.
Revvity Stock: Analyst Estimates & Ratings
Revvity has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.